Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human anti–pro...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Immunother Cancer
Glavni autori: Kaufman, Howard L., Russell, Jeffery S., Hamid, Omid, Bhatia, Shailender, Terheyden, Patrick, D’Angelo, Sandra P., Shih, Kent C., Lebbé, Céleste, Milella, Michele, Brownell, Isaac, Lewis, Karl D., Lorch, Jochen H., von Heydebreck, Anja, Hennessy, Meliessa, Nghiem, Paul
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Short Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5774167/
https://ncbi.nlm.nih.gov/pubmed/29347993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0310-x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items